---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123286"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:54:05.887734+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q3 net loss $24M; cash $360M; positive interim TYRA-300 mUC data

## Summary
- Net loss $24.0M in Q3 2024 vs $21.2M in Q3 2023; R&D expense $22.7M, up from $19.3M.
- Cash, equivalents, and marketable securities $360.1M; runway through at least 2026.
- TYRA-300 interim data: at ≥90 mg QD, 6/11 (54.5%) mUC patients with FGFR3+ had confirmed PR; 100% disease control.
- FDA cleared IND for Phase 2 achondroplasia study (BEACH301); first child dosing expected Q1 2025.
- Appointed Doug Warner as Chief Medical Officer, effective September 2024.

## SEC filing metadata
- accession: 0000950170-24-123286
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017024123286/0000950170-24-123286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017024123286/tyra-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123286
- JSON: https://secwatch.observer/filing/0000950170-24-123286.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.